IgA肾病:2021核心教程
该文是AJKD 2021年核心教程,系统综述IgA肾病的发病机制、临床表现、病理、预测工具与治疗。强调综合支持治疗为核心,免疫抑制治疗争议尚存,补体与黏膜免疫新靶点正在临床试验中。
要点
- 诊断金标准为肾活检IgA优势或共优势沉积。
- 综合支持治疗是初始治疗核心。
- 皮质类固醇降低蛋白尿但长期获益存疑且感染风险高。
核心结论
- IgA肾病治疗以综合支持治疗为核心,免疫抑制治疗争议尚存。
- 黏膜免疫与补体系统新靶点正在临床试验中评估。
研究设计与样本
- AJKD核心教程综述,回顾IgA肾病发病机制、临床表现、病理、预测工具与治疗,并附病例示例。
主要发现
- IgA肾病是全球最常见的原发性肾小球疾病。
- 诊断组织学标志为肾活检IgA优势或共优势沉积。
- 临床表现从无症状尿检异常到快速进展性肾小球肾炎不等。
- 在线风险计算器可用于预后评估并辅助与患者沟通。
- 皮质类固醇可降低蛋白尿,但长期获益存疑且与严重不良事件(尤其感染)相关。
临床怎么用
- 肾活检IgA优势或共优势沉积是诊断依据。
- 初始治疗以综合支持治疗为核心。
- 可用在线风险计算器辅助预后评估与患者沟通。
- 使用皮质类固醇需权衡蛋白尿降低与感染等严重不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease worldwide. The diagnostic histologic hallmark is dominant or codominant IgA staining on kidney biopsy; however, patients may present with various clinical syndromes ranging from asymptomatic abnormalities noted on urinalysis to rapidly progressive glomerulonephritis. Given substantial heterogeneity in the clinical course of disease, online risk calculators are available that may assist in prognostication and inform discussions with patients. Comprehensive supportive treatment is central in the initial therapy of IgAN; the additive benefit of currently available immunosuppressive agents remains an area of controversy. Although proteinuria is attenuated by the use of corticosteroids, the long-term benefits have been questioned, and the use of corticosteroids is associated with severe adverse effects, notably infection. Recent advances in our understanding of mucosal immunity and the role of the complement system in IgAN pathogenesis are leading to development of novel therapeutic options, which are being evaluated in ongoing clinical trials. In this installment of the AJKD Core Curriculum in Nephrology, IgAN pathogenesis, clinical manifestations, histology, prediction tools, and treatment are reviewed, and case examples are presented to illustrate the approach to the management of patients with IgAN.
引用
- Pattrapornpisut P, Avila-Casado C, Reich HN, et al. IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021. PMID: 34247883. doi:10.1053/j.ajkd.2021.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。